Literature DB >> 27325144

Effects of montelukast on M2-related cytokine and chemokine in M2 macrophages.

Yi-Ching Lin1, Ming-Yii Huang2, Min-Sheng Lee3, Chong-Chao Hsieh4, Hsuan-Fu Kuo5, Chang-Hung Kuo6, Chih-Hsing Hung7.   

Abstract

BACKGROUND/
PURPOSE: Asthma is a chronic airway inflammatory disease mediated by T-helper (Th)2 cells. Montelukast (trade name Singulair) is a cysteinyl leukotriene receptor antagonist used for asthma treatment. Mirroring Th1-Th2 polarization, two distinct states of macrophages have been recognized: the classically activated (M1) macrophages and the alternatively activated (M2) macrophages. M2 polarization is known to be a response to the Th2 cytokines; however, the effects of montelukast on M2 macrophages have not been well characterized. The aim of the present study was to investigate the effects of montelukast on the expression of cytokines and chemokines in M2-like macrophages, and to explore possible intracellular signaling pathways.
METHODS: The human monocytic leukemia cell line THP-1 and human monocytes from healthy donors were cultured with interleukin-4 for M2 polarization, and then the cells were pretreated with or without montelukast before lipopolysaccharide (LPS) stimulation. Supernatants were collected to determine interleukin-10, I-309/CCL1, and MDC/CCL22 levels by enzyme-linked immunosorbent assay. Intracellular signaling was investigated using nuclear factor (NF)-κB inhibitors, mitogen-activated protein kinase (MAPK) inhibitors, and western blot analysis.
RESULTS: LPS-induced interleukin-10 and I-309/CCL1 expression was significantly suppressed by montelukast in THP-1-derived and human monocyte-derived M2 macrophages after LPS stimulation. MDC/CCL22 expression was only significantly suppressed by montelukast in THP-1-derived M2 macrophages after 48 hours of incubation. In western blot analysis, montelukast was able to suppress LPS-induced MAPK-phospho-p38 and NF-κB-phospho-p65 expression.
CONCLUSION: Montelukast suppressed LPS-induced M2-related cytokines and chemokines in alternatively activated macrophages, and the effects might be mediated through the MAPK-p38 and NF-κB-p65 pathways.
Copyright © 2016. Published by Elsevier B.V.

Entities:  

Keywords:  Chemokine; M2 macrophage; Mitogen-activated protein kinase; Montelukast; Nuclear factor-κB

Mesh:

Substances:

Year:  2016        PMID: 27325144     DOI: 10.1016/j.jmii.2016.04.005

Source DB:  PubMed          Journal:  J Microbiol Immunol Infect        ISSN: 1684-1182            Impact factor:   4.399


  5 in total

1.  FNF-12, a novel benzylidene-chromanone derivative, attenuates inflammatory response in in vitro and in vivo asthma models mediated by M2-related Th2 cytokines via MAPK and NF-kB signaling.

Authors:  Mohammad Abohassan; Mesfer Al Shahrani; Mohammad Y Alshahrani; Naseem Begum; Suresh Radhakrishnan; Prasanna Rajagopalan
Journal:  Pharmacol Rep       Date:  2021-09-01       Impact factor: 3.024

2.  Montelukast alleviates inflammation in experimental autoimmune encephalomyelitis by altering Th17 differentiation in a mouse model.

Authors:  Bing Han; Yan-Yan Zhang; Ze-Qing Ye; Yun Xiao; Javad Rasouli; Wen-Cheng Wu; Su-Min Ye; Xin-Yue Guo; Lin Zhu; Abdolmohamad Rostami; Li-Bin Wang; Yuan Zhang; Xing Li
Journal:  Immunology       Date:  2021-02-28       Impact factor: 7.215

Review 3.  Montelukast: The New Therapeutic Option for the Treatment of Epilepsy.

Authors:  Bekalu Amare Tesfaye; Haftom Gebregergs Hailu; Kaleab Alemayehu Zewdie; Muluken Altaye Ayza; Derbew Fikadu Berhe
Journal:  J Exp Pharmacol       Date:  2021-01-20

4.  α-Ketoglutarate Upregulates Collecting Duct (Pro)renin Receptor Expression, Tubular Angiotensin II Formation, and Na+ Reabsorption During High Glucose Conditions.

Authors:  Aarón Guerrero; Bruna Visniauskas; Pilar Cárdenas; Stefanny M Figueroa; Jorge Vivanco; Nicolas Salinas-Parra; Patricio Araos; Quynh My Nguyen; Modar Kassan; Cristián A Amador; Minolfa C Prieto; Alexis A Gonzalez
Journal:  Front Cardiovasc Med       Date:  2021-06-04

5.  Montelukast drug activity and potential against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Authors:  Dennis C Copertino; Rodrigo R R Duarte; Timothy R Powell; Miguel de Mulder Rougvie; Douglas F Nixon
Journal:  J Med Virol       Date:  2020-07-19       Impact factor: 20.693

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.